Compare iShares Core Growth Allocation ETF (AOR) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Humana Inc — how do they compare? iShares Core Growth Allocation ETF trades at $68.84, while Humana Inc trades at $399.41 (market cap $47.09B). The key difference: Humana Inc pays a 0.9% dividend while iShares Core Growth Allocation ETF pays none. Which is the better fit depends on your goals.
| AOR | HUM | |
|---|---|---|
52-Week High | $69.85 | $409.42 |
52-Week Low | $61.00 | $163.67 |
Market Cap | — | $47.09B |
Sector | — | Health |
Enterprise Value | — | $56.13B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares Core Growth Allocation ETF (AOR) trades at $69.10, up 0.25% on the day, with a bearish technical signal from moving averages and neutral oscillators. The fund maintains a fixed 60/40 stock/bond allocation, rebalanced semiannually, with a low 0.20% expense ratio. Recent news highlights its role as a core holding but notes underperformance versus the S&P 500 over a decade.
Outlook: AOR offers diversified, low-cost exposure but faces headwinds from equity-bond correlation shifts. Risks include interest rate sensitivity and competition from pure equity funds. Analyst sentiment is mixed, balancing simplicity against relative returns.
Humana (HUM) trades at $392.22, down 1.39% on the day, with technical indicators showing a bullish trend despite near-term overbought signals. The company reported revenue growth to $129.66 billion in 2025 but faces margin compression, with net income margin declining to 0.82%. Recent news highlights strategic shifts, including the $900 million divestiture of its Gentiva stake and expansion of Medicaid contracts, while legal investigations into fiduciary duties and healthcare cost disclosures present headwinds.
The stock's outlook is mixed: bullish technicals and revenue growth contrast with margin pressures and legal risks. Analysts are cautious, with a consensus price target of $327.07 below the current price, suggesting limited upside. Investment opportunities lie in Humana's strategic focus on profitability and CenterWell growth, but risks include regulatory scrutiny and execution challenges in a competitive healthcare landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
